breezebio.com valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Verify with your agent

Paste this into your coding agent and it claims the listing for you. Valid, listed, verified profiles are eligible for search-engine visibility. Verified sites are listed by name in our llms-full.txt, the file agents read, and get a private dashboard for listing controls, file health, measured activity and score history.

Claim my listing on Agent Web Map for breezebio.com:
1. POST https://agentwebmap.com/v1/sites/breezebio.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://breezebio.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/breezebio.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/breezebio.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

BreezeBio

Precision genetic medicines powered by the NanoGalaxy® non-viral delivery platform, targeting autoimmune disease and oncology.

Authority: 50 reach 5 · trust 5 · quality 25 · freshness 15
Tier: listed
llms.txt: https://breezebio.com/llms.txt
llms-full.txt: https://breezebio.com/llms-full.txt
Sections: 6
Links: 22
Size: 5457 bytes
Popularity rank: #813182
For agents: Documentation: developer or product docs worth reading, nothing to call
First seen: 2026-10-19T10:44:57.358Z
Last checked: 2026-10-21T17:06:09.073Z
Badge

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T17:06:04.374Z. Cached copy · Source on breezebio.com

# BreezeBio

> Precision genetic medicines powered by the NanoGalaxy® non-viral delivery platform, targeting autoimmune disease and oncology.

Website: https://breezebio.com

Full version: https://breezebio.com/llms-full.txt (contains complete page content and full press release text)

## Organization

- Company: BreezeBio (formerly GenEdit)
- Industry: Biotechnology / Genetic Medicine
- Technology: NanoGalaxy® non-viral, non-lipid hydrophilic nanoparticle (HNP) delivery platform
- Payloads: mRNA, siRNA, DNA, CRISPR ribonucleoprotein
- Therapeutic Focus: Autoimmune disease (lead: BRZ-101 for type 1 diabetes), oncology
- Lead Candidate: BRZ-101 — mRNA-based immune tolerance therapy for type 1 diabetes (IND-enabling)
- Key Partnership: Multi-year collaboration with Genentech (Roche) for autoimmune indications; up to $629M in milestones
- CEO: Kunwoo (Ryan) Lee, Ph.D.
- Headquarters: South San Francisco, CA 94005
- Contact: info@breezebio.com

## Core Pages

- [Home](https://breezebio.com/): Main landing page — company overview and value proposition
- [Pipeline](https://breezebio.com/pipeline/): Therapeutic pipeline led by BRZ-101 for type 1 diabetes, plus oncology programs
- [Platform](https://breezebio.com/nanogalaxy/): NanoGalaxy® platform — proprietary HNP delivery technology with demonstrated targeting to immune, cardiac, pulmonary, and CNS tissues

## Scientific Context

- [Science](https://breezebio.com/science/): Scientific foundation of non-viral nanoparticle delivery for genetic medicines

## Corporate

- [About](https://breezebio.com/about/): Company history, leadership team, mission, and milestones
- [Careers](https://breezebio.com/careers/): Open positions and career opportunities
- [News](https://breezebio.com/news/): Press releases and company announcements
- [Contact](https://breezebio.com/contact/): Contact information and inquiry form

## News

- [BreezeBio Appoints Kevin Sin to Its Board of Directors](https://breezebio.com/breezebio-appoints-kevin-sin-to-its-board-of-directors/) - Press Releases (2026-09-15)
- [BreezeBio Presents Data Supporting NanoGalaxy® Platform for Antigen-Specific Immune Tolerance in Type 1 Diabetes at ADA 2026](https://breezebio.com/breezebio-presents-data-supporting-nanogalaxy-platform-for-antigen-specific-immune-tolerance-in-type-1-diabetes-at-ada-2026/) - Press Releases (2026-06-18)
- [BreezeBio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development](https://breezebio.com/breezebio-announces-scientific-advisory-board-to-support-next-stage-of-precision-genetic-medicine-pipeline-development/) - Press Releases (2026-05-26)
- [BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines](https://breezebio.com/breezebio-formerly-genedit-announces-series-b-financing-to-advance-internal-pipeline-of-precision-genetic-medicines/) - Press Releases (2026-02-25)
- [GenEdit Achieves First Milestone from Coll
…

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=breezebio.com · GET /v1/domain/breezebio.com · this page as Accept: application/json or text/markdown · MCP lookup_domain